Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV
Japanese approvals include Tecentriq for TNBC
Japan’s Ministry of Health, Labour and Welfare expanded the label of Tecentriq atezolizumab from Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) to include PD-L1-positive triple-negative breast cancer. MHLW also approved serotonin modulator and stimulator Trintellix vortioxetine from H. Lundbeck A/S (CSE:LUN) and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to treat major depressive disorder, and granted approval to HIF-PH inhibitor Evrenzo roxadustat from FibroGen Inc. (NASDAQ:FGEN) and Astellas Pharma Inc. (TSE:4503) for anemia associated with chronic kidney disease in dialysis-dependent patients.
AZ buys out Ironwood's rights to Linzess in China
AstraZeneca plc (LSE:AZN; NYSE:AZN) amended its 2012 deal with Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) to obtain exclusive rights to Linzess linaclotide in Greater China ahead of the drug's launch this half to treat constipation. Ironwood will receive $35 million in three installments and is eligible for $90 million in commercial milestones, plus royalties, but will no longer fund Linzess' development or share in profits in the territories. The deal covers China, Hong Kong and Macau...